FDA Delays Approval of Novo Nordisk's Once-Weekly Insulin Icodec
The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Novo Nordisk covering the Biologics License Application for once-weekly basal insulin icodec for the treatment of diabetes mellitus. In the letter, the FDA makes …